Together with previous findings, it's plausible to speculate that combination of EZH2 inhibitors and standard chemotherapy may have superior treatment efficiency against tongue cancer, although much work is still needed to further dissect the underlying mechanisms and substantiate the therapeutic advantages in animal models and clinical trials. The gene discussed is EZH2; the disease is tongue cancer.